 Eli Lilly and Co NYSE:LLY stock was moving higher as Roche revealed that an experimental rival treatment for Alzheimers failed in a Phase III clinical trial. Roche earlier today announced that its drug candidate gantenerumab failed to slow dementia progression in a twin drug trial Graduate 1 and 2. 